| Project/Area Number |
24390379
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGIHARA Kazuhiro 浜松医科大学, 医学部, 准教授 (00265878)
YAGUCHI Chiduko (SUZUKI Kazunao) 浜松医科大学, 医学部附属病院, 助教 (20397425)
TAMURA Naoaki 浜松医科大学, 医学部附属病院, 助教 (90402370)
UCHIDA Toshiyuki 浜松医科大学, 医学部附属病院, 講師 (90570234)
鈴木 一有 浜松医科大学, 医学部附属病院, 講師 (50456571)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2014: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2012: ¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
|
|---|
| Keywords | 羊水塞栓症 / C1インヒビター / ＤＩＣ / 羊水マーカー / アナフィラキシー / 補体 / DIC / フィブリノーゲン |
|---|
| Outline of Final Research Achievements |
We found that serum C3 and C4 levels were very low compared to normal pregnant women. We hypothesized that a marked reduction of C3 and C4 involved in C1 esterase inhibitor which controls complement system. We collected 106 cases of AFE had applied to the Japan AFE registration center in Hamamatsu University School of Medicine. In AFE cases, 85 cases were nonfatal and 21 cases were fatal. 88 women who delivered without AFE were regarded as a control. C1INH activity levels were significantly lower in AFE patients than in control women. C1INH activity levels in fatal AFE cases were significantly lower than those in nonfatal AFE cases. These results demonstrated that low C1INH activity levels was closely associated with the pathogenesis of AFE, suggesting that C1INH activity levels have potential as a prognosis factor of AFE. Also C1esterase inhibitor may be a promising candidate of treatment of AFE.
|
